A phase I, open label dose escalation study of the VEGF-C human monoclonal antibody VGX-100 administered by intravenous infusion alone and co-administered with bevacizumab in adult patients with advanced or metastatic solid tumors

Trial Profile

A phase I, open label dose escalation study of the VEGF-C human monoclonal antibody VGX-100 administered by intravenous infusion alone and co-administered with bevacizumab in adult patients with advanced or metastatic solid tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs VGX 100 (Primary) ; Bevacizumab
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Circadian Technologies; Vegenics
  • Most Recent Events

    • 21 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Nov 2017.
    • 21 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Sep 2017.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top